Board Change

Phytopharm PLC
20 June 2007


Company Contact:                               U.K. Investor Relations Contact:
Phytopharm plc                                 FD
Dr Daryl Rees CEO                              David Yates
Mr Piers Morgan CFO                            Ben Atwell
[phone]                               [phone]
www.phytopharm.com



                           Appointment of Chairman



GODMANCHESTER, Cambridgeshire, U.K. (20 June 2007) - Phytopharm plc (LSE: PYM)
('Phytopharm' or the 'Company') today announces the appointment of Alistair
Taylor as Non-Executive Chairman.  Mr Taylor will join the Board of Phytopharm
plc with effect from 18 July, succeeding Dr Paul Whitney who retires from the
Company after 10 years.  This appointment completes the planned restructuring of
the board.



Mr Taylor is currently Executive Chairman of UK listed Lombard Medical
Technologies plc and has 45 years experience in the healthcare industry, ten
years in pharmaceuticals and 35 years in medical devices.  He was Chief
Executive Officer of Biocompatibles International plc from 1994 to 1998 and
during this period the company progressed from a technology-based start up
company, through flotation to a FTSE 250 company.  Prior to this, Mr Taylor was
Chief Executive Officer of Schneider Inc, a Swiss interventional cardiology/
radiology device company and during this time the company's turnover grew to
$100 million. Schneider was subsequently sold by Pfizer Inc., its parent, for
over $2 billion.



During his extensive and successful career, Mr Taylor has made 13 acquisitions
of healthcare companies in USA, Europe and Japan, has taken two companies public
on the UK stock market, and raised over $300 million in public and private funds
in Europe and the USA.  Mr Taylor's early career included the Chief Accountant
role at Beecham Pharmaceuticals.  He is also Chairman of Starbridge Systems
Limited and a Non-Executive Director of Vascular Concepts Limited.



Commenting on today's announcement, Dr Paul Whitney, Chairman of Phytopharm plc,
said:



'I am delighted that we have attracted Alistair Taylor to be the next Chairman
of Phytopharm. His experience running major healthcare companies and the
insights gained from building these organizations into highly successful
businesses will be an important resource to the Company.  I know that I will be
leaving the company in capable hands with Alistair and the excellent executive
management and non-executive team.'



Commenting on today's announcement, Alistair Taylor said:



'I am pleased to be joining the Board at this exciting time when the business
has such strong further growth potential.  I look forward to working with the
executive team to continue Phytopharm's success and to explore additional
options for growth and the creation of shareholder value.'



There are no further disclosures to be made under paragraphs 9.6.13R of the
Listing Rules and 3.1.2R of the Disclosures Rules in respect of Mr Taylor.



                                     -Ends-



                                Notes to Editors



Phytopharm plc

Phytopharm is a pharmaceutical development and functional food company whose
product leads are generated from medicinal plants.  The Company's strategy is to
develop these products through 'proof of principle' clinical testing, and then
secure partners for late stage development, sales and marketing. Laboratory,
manufacturing and clinical work is outsourced to selected specialists, operating
under expert in-house management.  This operational structure allows access to
the best external research facilities whilst maintaining low fixed overheads and
a lower development cost structure.



For further information about Phytopharm please see our website at http://
www.phytopharm.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange